| Species | Human |
| Product Type | iPSC-derived Organoid |
| Quality Control | Negative for mycoplasma, bacteria, yeast, and fungi. |
| Tissue | Retinal |
| Disease | Normal |
| Generation Process | Stable and reproducible retinal organoids derived from human pluripotent stem cells (hPSCs) are generated using advanced differentiation protocols. These models recapitulate the complex architecture of the retina, providing an ideal platform for translational research in vision science. |
| Organoid Characterization | The human retina is broadly divided into the neural retina and the retinal pigmented epithelium. Retinal organoids express specific markers corresponding to each retinal layer. By approximately day 25 of culture, retinal ganglion cell and bipolar cell layers are observed, accompanied by expression of the marker Pax6. Analysis of cellular organization within the organoid, together with expression of the photosensitive cell marker Recoverin, confirms that these retinal organoids closely resemble native human retinal tissue. |
| Applications | These models support accurate drug screening for conditions including retinitis pigmentosa and age-related macular degeneration, accelerating advances in vision science and treatment innovation. |
| Storage | Liquid Nitrogen |
| Shipping Information | Dry Ice |
For preclinical research and development use only; not intended for therapeutic or other applications.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.